Most Common Side Effects of Entresto
Entresto (sacubitril/valsartan), used for heart failure, most often causes hyperkalemia (high potassium levels, 16-18% of patients), hypotension (low blood pressure, 10-18%), and renal impairment (12-13%). Cough occurs in about 9% of users.[1][2]
How Often Do These Happen?
In clinical trials like PARADIGM-HF (8,442 patients):
- Hyperkalemia: 16% on Entresto vs. 12% on enalapril.
- Hypotension: 14% vs. 9.2%.
- Elevated creatinine (kidney marker): 12.9% vs. 11.3%.
- Cough: 8.9% vs. 16.6% (less common than ACE inhibitors).
These rates come from the drug's prescribing information and FDA label, reflecting doses up to 97/103 mg twice daily.[1][2]
Serious Side Effects Patients Report
Angioedema (swelling, especially face/lips/tongue) affects 0.5% (higher risk in Black patients at 2.4%). Other risks include fetal toxicity (avoid in pregnancy), symptomatic hypotension in volume-depleted patients, and neutropenia. Monitor potassium and kidney function regularly.[1][2]
Who Gets Side Effects Most?
Elderly patients (over 75) see higher rates of renal issues (19%) and hyperkalemia (21%). Those with low blood pressure at start or on diuretics face more hypotension. Real-world data aligns with trials, though post-marketing reports note dizziness (6-9%) and fatigue.[2][3]
Managing or Avoiding Side Effects
Start at low dose (24/26 mg twice daily) and titrate slowly. Hold or reduce if hypotension persists. Potassium binders help hyperkalemia. Avoid with ACE/ARB inhibitors (risks angioedema). Inform doctor of dehydration or salt substitutes before starting.[1]
How Does Entresto Compare to Alternatives?
Vs. enalapril: Fewer cough cases but more hyperkalemia/hypotension. Vs. beta-blockers like carvedilol: Similar renal risks, but Entresto adds unique potassium issues. Patients switching from ACE inhibitors often report less cough.[2]
[1]: Entresto Prescribing Information (Novartis, FDA)
[2]: PARADIGM-HF Trial Data (NEJM)
[3]: Drugs.com Entresto Side Effects